HAEMONETICS CORP — Director's Dealing 2025

Jun 9, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2025-06-05

Reporting Person: Maunsell Farris Maryanne (VP, Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-05	Common Stock	A	2662	—	Acquired	4478	Direct

Footnotes

F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. Two-thirds of the RSUs vest in two equal annual installments beginning on the first anniversary of the date of grant and one-third of the RSUs vests based on the Issuer's common stock price at the end of a two-year performance period.

F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3: This number includes unvested RSUs previously reported.